Fig. 2: The median OS since diagnosis for ALK-positive lung cancer patients who received Lorlatinib as part of their treatment in second-line and beyond was 55 months (95% CI: 42.6–67.4).
Kaplan–Meier survival curves depicting the overall survival of ALK-positive patients who received Lorlatinib.
